Oncotarget is a peer-reviewed publication launched in 2010. Impact Journals host it. The journal is published online on a weekly basis. The publication focuses on medical professionals primarily oncologists. It has recently expanded to accommodate numerous other sections. Mikhail Blagosklonny founded the journal. He serves as the editor-in-chief together with Andrei Gudkov. The two are leading scientists attached to the Roswell Park Cancer Institute in Buffalo, New York.
Mikhail Blagosklonny has achieved legendary success with anti-aging therapies as a treatment option for cancer. The leadership comprises of some of the most prominent scientists and researchers in the world. The journal is indexed by popular online platforms such as PubMed, Scopus, and BIOSIS Previews among others. Oncotarget employs an open access policy. This means there are no restrictions on access and use. You can easily access the papers from their online portal. The journal is peer reviewed and is published by Impact Journals.
Oncotarget is dedicated to helping people achieve a life without disease. The journal hopes to raise awareness and foster collaboration among the various stakeholders. It focuses on maximizing the impact of research through an insightful peer-review model. It helps researchers achieve more reach with their papers. It makes scientific papers available rapidly and to a larger audience. The journal has been widely successful prompting the leadership to embrace other topics.
Besides Oncology, the journal handles other subjects such as pharmacology, neuroscience, cardiology and cell biology among many other disciplines.
Oncotarget is famous with scientists for its peer-review model. Authors and contributors can select the particular peers to participate in reviewing their paper. The review is quick enabling faster distribution of the research papers. The author will receive a response within a month.
Oncotarget prides itself in offering strict review guidelines. This ensures the process is credible and trusted to approve quality papers. The platform encourages authors with papers that have been questionably rejected to submit them to Oncotarget. Oncotarget is also available on Dove Press.
The journal offers superior reporting through altmetrics. This enables transparent and reliable monitoring of the distribution process. Authors can quickly obtain information on how many people have accessed and cited their papers. The forum provides a platform for medical professionals from numerous disciplines to exchange information, share research and experiences with regarding therapy techniques.